Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 12/20 | 1.00 |
| ▸ | PLA2G4A | P47712 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 1.00 |
| ▸ | MGLL | Q99685 | 1/20 | 1.00 |
| ▸ | PLA2G4C | Q9UP65 | 1/20 | 1.00 |
| ▸ | CES1 | P23141 | 7/20 | 0.81 |
| ▸ | PPARG | P37231 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.64 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arachidonyl Trifluoromethylketone SCHEMBL30426991 | 1.00 | FAAH (1.00) | FAAHPLA2G4AALDH1A1MAPTBLM | |
| SCHEMBL459981 | 0.97 | FAAH (0.93) | FAAHPLA2G4AALDH1A1MAPTBLM | |
| SCHEMBL459980 | 0.97 | FAAH (0.93) | FAAHPLA2G4AALDH1A1MAPTBLM | |
| SCHEMBL3679974 | 0.95 | FAAH (0.90) | FAAHPLA2G4AALDH1A1MAPTBLM | |
| SCHEMBL3679976 | 0.95 | FAAH (0.90) | FAAHPLA2G4AALDH1A1MAPTBLM | |
| SCHEMBL22195368 | 0.93 | FAAH (0.88) | FAAHPLA2G4AALDH1A1MAPTBLM | |
| Arachidonic Acid SCHEMBL28819351 | 0.92 | ALDH1A1 (0.85) | FAAHPLA2G4AALDH1A1MAPTBLM | |
| SCHEMBL22195422 | 0.92 | FAAH (0.85) | FAAHPLA2G4AALDH1A1MAPTBLM | |
| SCHEMBL22222739 | 0.91 | FAAH (0.84) | FAAHPLA2G4AALDH1A1MAPTBLM | |
| SCHEMBL24938529 | 0.89 | FAAH (1.00) | FAAHPLA2G4AALDH1A1MAPTBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250352615-A1 | COMPOSITIONS AND METHODS FOR THE MODULATION OF PIEZO1 AND TRPV4 | UNIV DUKE (US) | 2025-11-20 | — | — | US | claimed |
| CN-118846067-A | Medicament for preventing or treating scar pregnancy | 北京航空航天大学 | 2024-10-29 | — | — | CN | claimed |
| WO-2024073476-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER BY REDUCING THE EXPRESSION AND/OR ACTIVITY OF PLA2G10 | YALE UNIVERSITY (US) | 2024-04-04 | — | — | WO | claimed |
| EP-4243805-A1 | COMBINATION THERAPIES FOR TREATING CORONAVIRUS INFECTION | Gbiotech S.À.R.L. (CH) | 2023-09-20 | — | — | EP | claimed |
| WO-2023091901-A1 | COMPOSITIONS AND METHODS FOR THE MODULATION OF PIEZO1 AND TRPV4 | DUKE UNIVERSITY (US) | 2023-05-25 | — | — | WO | claimed |
| US-20230060937-A1 | SIMULTANEOUS GENE EDITING AND HAPLOID INDUCTION | SYNGENTA PARTICIPATIONS AG (CH) | 2023-03-02 | — | — | US | claimed |
| WO-2022029334-A1 | COMBINATION THERAPIES FOR TREATING CORONAVIRUS INFECTION | GBIOTECH S.À.R.L. (CH) | 2022-02-10 | — | — | WO | claimed |
| US-20260137041-A1 | SIMULTANEOUS GENE EDITING AND HAPLOID INDUCTION | SYNGENTA CROP PROTECTION AG (CH) | 2026-05-21 | — | — | US | disclosed |
| EP-4735431-A2 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735446-A1 | SALTS AND SOLID FORMS OF A COMPOUND THAT MODULATES IRAK4 | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12593765-B2 | Simultaneous gene editing and haploid induction | SYNGENTA CROP PROTECTION AG (CH) | 2026-04-07 | — | — | US | disclosed |
| US-12590309-B2 | Reprogramming of lipid metabolism to inhibit T cell senescence and enhance tumor immunotherapy | SAINT LOUIS UNIVERSITY (US) | 2026-03-31 | — | — | US | disclosed |
| EP-3509604-B1 | COMBINATION THERAPIES USING IMMUNO-DASH INHIBITORS AND PGE2 ANTAGONISTS | TUFTS COLLEGE (US) | 2026-02-18 | — | — | EP | disclosed |
| US-8796251-B2 | Compositions and methods for the treatment of glomerulonephritis | AVEXXIN AS (NO) | 2014-08-05 | — | — | US | disclosed |
| EP-2745837-A1 | Glomerulonephritis Treatment | Avexxin AS (NO) | 2014-06-25 | — | — | EP | disclosed |
| US-20120136066-A1 | Glomerulonephritis Treatment | AVEXXIN AS (NO) | 2012-05-31 | — | — | US | disclosed |
| US-20120136066-A1 | Glomerulonephritis Treatment | AVEXXIN AS (NO) | 2012-05-31 | — | — | US | disclosed |
| US-20100311843-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GLOMERULONEPHRITIS | AVEXXIN AS (NO) | 2010-12-09 | — | — | US | disclosed |
| WO-2010139482-A1 | GLOMERULONEPHRITIS TREATMENT | AVEXXIN AS (NO) | 2010-12-09 | — | — | WO | disclosed |
| EP-0860168-B1 | Use of central cannbinoid receptor CB1 agonists | BAYER HEALTHCARE AG (DE) | 2007-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12590309-B2 | Reprogramming of lipid metabolism to inhibit T cell senescence and enhance tumor immunotherapy | PLA2G4A, PLA2G2A, PLA2G1B | FAAH 966/4885PLA2G4A 1/4885ALDH1A1 3735/4885 |
| US-20260137041-A1 | SIMULTANEOUS GENE EDITING AND HAPLOID INDUCTION | CPSF1, RNGTT, PAPSS1 | FAAH 2447/4885PLA2G4A 18/4885ALDH1A1 3855/4885 |
| US-20120136066-A1 | Glomerulonephritis Treatment | SSB, REN, GRHPR | FAAH 2933/4885PLA2G4A 2333/4885ALDH1A1 3185/4885 |
| US-20250352615-A1 | COMPOSITIONS AND METHODS FOR THE MODULATION OF PIEZO1 AND TRPV4 | PIEZO1, PLA2G4A, TRPV4 | FAAH 818/4885PLA2G4A 2/4885ALDH1A1 2756/4885 |
| US-20100311843-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GLOMERULONEPHRITIS | REN, SSB, C5 | FAAH 2431/4885PLA2G4A 1973/4885ALDH1A1 3753/4885 |
| US-12593765-B2 | Simultaneous gene editing and haploid induction | CPSF1, PAPSS1, RNGTT | FAAH 2303/4885PLA2G4A 20/4885ALDH1A1 4201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.